Significant Improvement in Tuberculosis Diagnosis by Detection of the Wall Lipoarabinomannan from Mycobacterium tuberculosis in Central African Republic (CAR)
Background and Objective: Tuberculosis is one
of the leading causes of morbi-mortality, especially in developing countries,
due to delayed diagnosis and management. The goal of this study is to assess
the contribution of lipoarabinomannan (LAM) in improving tuberculosis (TB) diagnosis
in the Central African Republic (C.A.R.). Methods: We conducted a
retrospective study at the Regional University Hospital of Bria. The records of
patients hospitalized, tested by Determine® TB LAM Ag (Alere,
Medical Co, LTD, Chiba, Japan) immunochromatographic
test for the detection of LAM in urine, associated or not with acid-fast
bacilli (AFB) research by Ziehl-Neelsen stain, were selected from August
to October 2020. Results: During this study, 152 files were selected.
Among them, there were 50.0% of children aged 14 or less (≤14 years: 33.6%+16.4%) and 50.0% of adults represented. Patients living in the displaced
person camp represented a larger group (65.1%) than those in the other 2 sites.
There were seventy-four patients (i.e. 48.7%) who did not benefit from screening for AFB. For the other seventy-eight (i.e. 51.3%), there were 17.1% positive results for the search of AFB. However, among
the 152 patients, there was a positive HIV serology in 30.9% of cases (i.e. 47 out of 152) and a positive Determine
References
[1]
World Health Organization (WHO) (2019) Global Tuberculosis Report 2019. World Health Organization, Geneva. https://www.who.int/publications/i/item/9789241565714
[2]
World Health Organization (WHO) (2020) Global Tuberculosis Report 2020. World Health Organization, Geneva. https://www.who.int/publications/i/item/9789240013131
[3]
Charbonnier, F., Janssens, J.P., Calmy, A. (2011) Co-infection tuberculose et VIH: Enjeux thérapeutiques. Revue Médicale Suisse, 7, 2295-2300.
[4]
Kanabus, A. (2020) Information about Tuberculosis, GHE, 2020. http://www.tbfacts.org
[5]
Pembe, I.M., Niama, R.F., Nguimbi, E., Ahombo, G., Kombo Mouingou, S.B., Kouhounina, B.G.D., Madzou-Laboum, I.K., Mombouli, J.V. and Parra, H.J. (2017) Place du Determine TB-LAM Ag dans le diagnostic de la tuberculose en République du Congo. Sciences de la santé, 5, 30-35.
[6]
World Health Organization (WHO) (2008) Implementing the WHO Stop TB Strategy: A Handbook for National Tuberculosis Control Programmes. World Health Organization, Geneva, (WHO/HTM/TB/2008.401).
[7]
World Health Organization (WHO) (2017) Framework for Implementing the “End TB Strategy” in the African Region 2016-2020. https://www.afro.who.int/publications/framework-implementing-end-tb-strategy-african-region-2016-2020
[8]
World Health Organization (WHO) (2018) Global Tuberculosis Report 2018. World Health Organization, Geneva. https://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646eng.pdf?sequence=1&is Allowed=y
[9]
World Health Organization (WHO) (2018) Millennium Development Goals (MDGs). https://www.who.int/news-room/fact-sheets/detail/millennium-development-goals-(mdgs)
[10]
Zijenah, L.S., Kadzirange, G., Bandason, T., Chipiti, M.M., Gwambiwa, B., Makoga, F., Chungu, P., Kaguru, P. and Dheda, K. (2016) Comparative Performance Characteristics of the Urine Lipoarabinomannan Strip Test and Sputum Smear Microscopy in Hospitalized HIV-Infected Patients with Suspected Tuberculosis in Harare, Zimbabwe. BMC Infectious Diseases, 16, Article No. 20. https://doi.org/10.1186/s12879-016-1339-z
[11]
Boehme, C., Molokova, E., MinjaF, Geis, S., Loscher, T., Maboko, L., Koulchin, V. and Hoelscher, M. (2005) Detection of Mycobacterial Lipoarabinomannan with an Antigene-Capture ELISA in Unprocessed Urine of Tanzanian Patients with Suspected Tuberculosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 99, 893-900. https://doi.org/10.1016/j.trstmh.2005.04.014
[12]
Cox, J.A., Lukande, R.L., Kalungi, S., Van Marck, E., Lammens, M., Van de Vijver, K., Kambugu, A., Nelson, A.M., Colebunders, R. and Manabe, Y.C. (2015) Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid to Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults. Journal of Clinical Microbiology, 53, 2667-2673. https://doi.org/10.1128/JCM.00624-15
[13]
Shah, M., Ssengooba, W., Armstrong, D., Nakiyingi, L., Holshouser, M., llner, J.J., Joloba, M., Manabe, Y.C. and Dormana, S.E. (2014) Comparative Performance of Urinary Lipoarabinomannan Assays and Xpert MTB/RIF in HIV-Infected Individuals with Suspected Tuberculosis in Uganda. AIDS, 28, 1307-1314. https://doi.org/10.1097/QAD.0000000000000264
[14]
Ministère de la Santé et de la Population de la République Centrafricaine (MSP-RCA) (2018) Rapport d’activités 2018 du Programme National de Lutte contre la Tuberculose. MSP-RCA, Bangui, 50 p.
[15]
Elmorsy, A., Shalaby, N., Zaghloul, M., Hewidy, A., Elhalawany, N., El-Shahawy, H. and Fathy, A. (2017) Role of Detection of Lipoarabinomannan (LAM) in Urine for Diagnosis of Tuberculosis in HIV Patients; Egyptian Experience. European Respiratory Journal, 50, Article No. PA3040. https://doi.org/10.1183/1393003.congress-2017.PA3040
[16]
World Health Organization (WHO) (2006) Global Tuberculosis Control: Surveillance, Planning, Financing. World Health Organization, Geneva. (WHO/HTM/TB/2006.362).
[17]
Aroui, H., Maoua, M., Koubaa, A., Kacem, I., Gaddour, A., Guedri, S., Aissa, S., Brahem, A., Kalboussi, H., Chatti, S., El Maalel, O. and Mrizek, N. (2020) Tuberculose pulmonaire commune et activité professionnelle. Archives des Maladies Professionnelles et de l’Environnement, 81, 723-724. https://doi.org/10.1016/j.admp.2020.03.764
[18]
Joint United Nations Programme on HIV/AIDS (2019) UNAIDS Data 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf
[19]
World Health Organization (WHO) (2017) Global Tuberculosis Report 2017. World Health Organization, Geneva.
[20]
Chakaya, J., Khan, M., Ntoumi, F., Aklillu, E., Fatima, R., Mwaba, P., Kapata, N.,Mfinanga S Hasnain, S.E., Katoto, P.D.M.C., Bulabula, A.N.H., Sam-Agudu, N.A., Nachega, J.B., Tiberi, S., McHugh, T.D., Abubakar, I. and Zumla, A. (2021) Global Tuberculosis Report 2020—Reflections on the Global TB Burden, Treatment and Prevention Efforts. International Journal of Infectious Diseases 113, S7-S12. https://doi.org/10.1016/j.ijid.2021.02.107
[21]
World Health Organization (WHO) (2015) Consolidated Guidelines on HIV Testing Services: 5Cs: Consent, Confidentiality, Counselling, Correct Results and Connection 2015. World Health Organization, Geneva https://apps.who.int/iris/handle/10665/179870
[22]
Mugusi, F., Villamor, E., Urassa, W., Saathoff, E., Bosch, R.J. and Fawzi, W.W. (2006) HIV Co-Infection, CD4 Cell Counts and Clinical Correlates of Bacillary Density in Pulmonary Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 10, 663-669.
[23]
World Health Organization (WHO) (2019) Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis of Active Tuberculosis in People Living with HIV: Policy Update (2019). World Health Organization, Geneva. https://apps.who.int/iris/bitstream/handle/10665/329479/9789241550604eng.pdf?sequence=1&isAllowed=y&ua=1
[24]
Lawn, S., Kerkhoff, A., Burton, R., Schutz, C., Boulle, A., Vogt, M., Gupta-Wright, A., Nicol, M.P. and Meintjes, G. (2017) Diagnostic Accuracy, Incremental Yield and Prognostic Value of Determine TB-LAM for Routine Diagnostic Testing for Tuberculosis in HIV-Infected Patients Requiring Acute Hospital Admission in South Africa: A Prospective Cohort. BMC Medicine, 15, Article No. 67. https://doi.org/10.1186/s12916-017-0822-8
[25]
Broger, T., Sossen, B., du Toit, E., Kerkhoff, A.D., Schutz, C., Reipold, E.I., Ward, A., Barr, D.A., Macé, A., Trollip, A., Burton, R., Ongarello, S., Pinter, A., LowaryTL, Boehme, C., Nicol, M.P., Meintjes, G. and Denkinger, C.M. (2019) Novel Lipoarabinomannan Point-of-Care Tuberculosis Test for People with HIV: A Diagnostic Accuracy Study. The Lancet Infectious Diseases, 19, 852-861. https://doi.org/10.1016/S1473-3099(19)30001-5
[26]
Singhroy, D.N., MacLean, E., Kohli, M., Lessem, E., Branigan, D., England, K., Suleiman, K., Drain, P.K., Ruhwald, M., Schumacher, S., Denkinger, C.M., Waning, B., Van Gemert, W. and Pai, M. (2020) Adoption and Uptake of the Lateral Flow Urine LAM Test in Countries with High Tuberculosis and HIV/AIDS Burden: Current Landscape and Barriers. Gates Open Research, 4, Article No. 24. https://doi.org/10.12688/gatesopenres.13112.1
[27]
Peter, J.G., Ziejenah, L.S., Chanda, D., Peter, J.G., Zijenah, L.S., Chanda, D., Clowes, P., Lesosky, M., Gina, P., Mehta, N., Calligaro, G., Lombard, C.L., Kadzirange, G., Bandason, T., Chansa, A., Liusha, N., Mangu, C., Mtafya, B., Msila, H., Rachow, A., Hoelscher, M., Mwaba, P., Theron, G. and Dheda, K. (2016) Effect on Mortality of Point-of-Care, Urine-Based Lipoarabinomannan Testing to Guide Tuberculosis Treatment Initiation in HIV-Positive Hospital Inpatients: A Pragmatic, Parallel- Group, Multicountry, Open-Label, Randomised Controlled Trial. Lancet, 387, 1187-1197. https://doi.org/10.1016/S0140-6736(15)01092-2
[28]
World Health Organization (WHO) (2019) Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for the Diagnosis of Active Tuberculosis in People Living with HIV: Policy Update (2019). World Health Organization, Geneva.
[29]
Treatement Action Group (TAG) (2020) An Activist’s Guide to the LAM Test Vital for Diagnosing TB in People Living with HIV/AIDS. https://www.treatmentactiongroup.org/publication/an-activists-guide-to-the-tb-lam-test/
